New drug cocktail targets Hard-to-Treat cancers

This early-phase trial is testing whether combining two targeted drugs, pemigatinib and afatinib, is safe and can shrink tumors in people with advanced solid cancers that have specific FGTR gene changes. The study includes up to 70 participants whose cancers have spread or cannot be removed and have not responded to standard treatments. Researchers will first find the highest tolerable doses, then check how well the combination works in a specific type of bile duct cancer.